Journal
NEUROSCIENCE
Volume 355, Issue -, Pages 188-199Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuroscience.2017.05.005
Keywords
Alzheimer's disease; mTOR; rapamycin; A beta(25-35); neuronal inflammation; NF-kappa B signaling
Categories
Funding
- Fujian Medical University [2009bs002, JS14003]
Ask authors/readers for more resources
Rapamycin (RAPA), an inhibitor of mammalian target of rapamycin (mTOR), exhibits a high neuroprotective action against neurodegenerative diseases in mouse models. Since neuroinflammation has been shown to be involved in Alzheimer's disease (AD) development and progression, the aim of this study was to examine the anti-inflammatory role of RAPA in AD in vivo and in vitro, and investigate the underlying mechanisms. We found that amyloid-beta (A beta) induced neuronal inflammation and a remarkable increase in mTOR activity in in-vivo and in-vitro models of inflammation, suggesting the critical role of mTOR signaling in neuronal inflammation. In addition, administration of RAPA was found to down-regulate mTOR, p-mTOR, Nuclear factor kappa B (NF-kappa B) p65, p-p65, TNF-alpha, IL-1 beta and Bax protein expression in AP(25-35)-or lipopolysaccharides (LPS)treated mice and cultured Neuro-2a (N2a) cells. Moreover, RAPA disrupted A(25-35)-induced nuclear translocation of mTOR and NF-kappa B. Our findings indicate that RAPA inhibits A beta(25-35)- or LPS-induced neuronal inflammation through suppressing mTOR signaling and reducing nuclear import of NF-KB. (C) 2017 IBRO. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available